Skip to main content
Clinical Trials/NCT05330130
NCT05330130
Completed
Phase 1

Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI on the Expression of FSH- and LH-receptors in Granulosa Cells

ART Fertility Clinics LLC1 site in 1 country6 target enrollmentJuly 5, 2023

Overview

Phase
Phase 1
Intervention
Follitropin beta injection 150 IU
Conditions
Ovarian Function Insufficiency
Sponsor
ART Fertility Clinics LLC
Enrollment
6
Locations
1
Primary Endpoint
Number of FSHR- and LHR of the GC, obtained from one follicle on the morning of day 5, before the administration of the first GnRH-antagonist, punctured during the ovarian stimulation cycle
Status
Completed
Last Updated
last year

Overview

Brief Summary

To study the influence of different daily rec-FSH dosages (150 IU versus 300 IU), performed in the same patient in consecutive cycles, on the relation between FSH- and LH-receptors of the granulosa cells of the growing follicle.

Detailed Description

This is a prospective cross-over study. Investigators want to study the effect of different dosages of recombinant FSH in the same patient on the expression of the FSH- and LH-receptors in the granulosa cells and on the endocrine milieu in the blood and the follicular fluid. An improved understanding of the mechanism leading to progesterone elevation might initiate a change in the ovarian stimulation approach, thereby not only preventing progesterone elevation and its negative consequences on ART (Assisted Reproductive Technology) outcome, but also improving individualization of the ovarian stimulation treatment according to the patients' characteristics.

Registry
clinicaltrials.gov
Start Date
July 5, 2023
End Date
June 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Crossover
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Barbara Lawrenz

Scientific Director

ART Fertility Clinics LLC

Eligibility Criteria

Inclusion Criteria

  • Desire to perform oocyte freezing for social fertility preservation, age 18 - 38 years
  • BMI of 18-32 kg/m2
  • Regular menstrual cycles with a length of 24-35 days
  • Anti-Muellerian-Hormone levels between 1.3 - 6.25 ng/ml (Ferraretti and Gianaroli, 2014; Calzada et al., 2019)

Exclusion Criteria

  • Occurrence of ovarian hyperstimulation syndrome (OHSS)
  • Occurrence of poor ovarian response (AFC \< 5 and AMH \< 0,5ng/ml) in previous ovarian stimulation treatment (20)
  • Polycystic ovary syndrome (PCOS) (21)

Arms & Interventions

Daily 150 IU recFSH

Follitropin beta injection 150 IU daily

Intervention: Follitropin beta injection 150 IU

Daily 300 IU recFSH

Follitropin beta injection 300 IU daily

Intervention: Follitropin beta injection 300 IU

Outcomes

Primary Outcomes

Number of FSHR- and LHR of the GC, obtained from one follicle on the morning of day 5, before the administration of the first GnRH-antagonist, punctured during the ovarian stimulation cycle

Time Frame: 5 days

Number of FSHR- and LHR of the GC, obtained from tone follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm, punctured during the ovarian stimulation cycle

Time Frame: 1 day

Number of FSHR- and LHR of the GC, obtained from two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation, punctured during the ovarian stimulation cycle

Time Frame: 1 day

Number of FSHR- and LHR of the GC, obtained from the follicular fluid of follicles aspirated during OPU

Time Frame: 1 day

Secondary Outcomes

  • Level of FSH hormone in the blood, on the day of OPU(1 day)
  • Level of P4 hormone in the blood, on the day of OPU(1 day)
  • Level of E2 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist(5 days)
  • Level of P4 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist(5 days)
  • Level of FSH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist(5 days)
  • Level of LH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist(5 days)
  • Level of E2 hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm(1 day)
  • Level of P4 hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm(1 day)
  • Level of FSH hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm(1 day)
  • Level of LH hormone in the blood, when there are at least 2 to 3 follicles with a size of 12 to 14 mm(1 day)
  • Level of P4 hormone in the blood, on the morning of the day of final oocyte maturation(1 day)
  • Level of E2 hormone in the blood, on the morning of the day of final oocyte maturation(1 day)
  • Level of LH hormone in the blood, on the morning of the day of final oocyte maturation(1 day)
  • Level of E2 hormone in the blood, on the day of OPU(1 day)
  • Level of FSH hormone in the blood, on the morning of the day of final oocyte maturation(1 day)
  • Level of P4 hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist(5 days)
  • Level of FSH hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist(5 days)
  • Level of LH hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist(5 days)
  • Level of LH hormone in the blood, on the day of OPU(1 day)
  • Level of E2 hormone in the follicular fluid of one follicle on the morning of day 5, before the administration of the first GnRH-antagonist(5 days)
  • Level of E2 hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm(1 day)
  • Level of P4 hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm(1 day)
  • Level of FSH hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm(1 day)
  • Level of LH hormone in the follicular fluid of one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm(1 day)
  • Level of E2 hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation(1 day)
  • Level of P4 hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation(1 day)
  • Level of FSH hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation(1 day)
  • Level of LH hormone in the follicular fluid of two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation(1 day)
  • Level of E2 hormone in the follicular fluid of follicles aspirated during OPU(1 day)
  • Level of P4 hormone in the follicular fluid of follicles aspirated during OPU(1 day)
  • Level of FSH hormone in the follicular fluid of follicles aspirated during OPU(1 day)
  • Level of LH hormone in the follicular fluid of follicles aspirated during OPU(1 day)

Study Sites (1)

Loading locations...

Similar Trials